tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

MIRM Stock Latest News

Mirum Pharmaceuticals price target raised to $77 from $53 at JPMorgan
The FlyMirum Pharmaceuticals price target raised to $77 from $53 at JPMorgan
6d ago
MIRM
Mirum Pharmaceuticals completes enrollment in VISTAS study of volixibat
PremiumThe Fly
Mirum Pharmaceuticals completes enrollment in VISTAS study of volixibat
10d ago
MIRM
Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PBC Treatment
PremiumCompany Announcements
Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PBC Treatment
27d ago
MIRM
Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PSC Treatment
PremiumCompany Announcements
Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PSC Treatment
28d ago
MIRM
Mirum Pharmaceuticals files automatic mixed securities shelf
PremiumThe Fly
Mirum Pharmaceuticals files automatic mixed securities shelf
1M ago
MIRM
Arm initiated, Adobe downgraded: Wall Street’s top analyst calls
PremiumThe FlyArm initiated, Adobe downgraded: Wall Street’s top analyst calls
1M ago
UE
ARM
Mirum Pharmaceuticals resumed with a Buy at Stifel
Premium
The Fly
Mirum Pharmaceuticals resumed with a Buy at Stifel
1M ago
MIRM
Mirum Pharmaceuticals: Strong Buy Rating Backed by Robust Growth Prospects in Rare Disease Market
Premium
Ratings
Mirum Pharmaceuticals: Strong Buy Rating Backed by Robust Growth Prospects in Rare Disease Market
1M ago
MIRM
Buy Rating Affirmed for Mirum Pharmaceuticals Amid Strong Financial Performance and Growth Potential
PremiumRatings
Buy Rating Affirmed for Mirum Pharmaceuticals Amid Strong Financial Performance and Growth Potential
1M ago
MIRM
Mirum Pharmaceuticals Reports Strong Q2 Growth and Raises Guidance
PremiumCompany Announcements
Mirum Pharmaceuticals Reports Strong Q2 Growth and Raises Guidance
1M ago
MIRM
Mirum Pharmaceuticals price target raised to $82 from $77 at Raymond James
PremiumThe Fly
Mirum Pharmaceuticals price target raised to $82 from $77 at Raymond James
1M ago
MIRM
Mirum Pharmaceuticals price target raised to $81 from $79 at Citizens JMP
PremiumThe Fly
Mirum Pharmaceuticals price target raised to $81 from $79 at Citizens JMP
1M ago
MIRM
Mirum Pharmaceuticals price target raised to $80 from $73 at H.C. Wainwright
PremiumThe FlyMirum Pharmaceuticals price target raised to $80 from $73 at H.C. Wainwright
1M ago
MIRM
Strong Commercial Performance and Strategic Initiatives Drive Buy Rating for Mirum Pharmaceuticals
Premium
Ratings
Strong Commercial Performance and Strategic Initiatives Drive Buy Rating for Mirum Pharmaceuticals
1M ago
MIRM
Mirum Pharmaceuticals Reports Strong Q2 2025 Growth
Premium
Company Announcements
Mirum Pharmaceuticals Reports Strong Q2 2025 Growth
1M ago
MIRM
Mirum Pharmaceuticals reports Q2 EPS (12c), consensus (33c)
PremiumThe Fly
Mirum Pharmaceuticals reports Q2 EPS (12c), consensus (33c)
1M ago
MIRM
Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PBC Treatment
PremiumCompany Announcements
Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PBC Treatment
2M ago
MIRM
Mirum Pharmaceuticals Advances Phase 3 Study on Maralixibat for Cholestatic Pruritus
PremiumCompany Announcements
Mirum Pharmaceuticals Advances Phase 3 Study on Maralixibat for Cholestatic Pruritus
2M ago
MIRM
Mirum Pharmaceuticals price target raised to $76 from $68 at Evercore ISI
PremiumThe Fly
Mirum Pharmaceuticals price target raised to $76 from $68 at Evercore ISI
2M ago
MIRM
Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PBC Treatment
PremiumCompany AnnouncementsMirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PBC Treatment
3M ago
MIRM
Mirum Pharmaceuticals Holds 2025 Annual Stockholders Meeting
Premium
Company Announcements
Mirum Pharmaceuticals Holds 2025 Annual Stockholders Meeting
4M ago
8K
MIRM
Mirum Pharmaceuticals appoints Doug Sheehy as Chief Legal Officer
Premium
The Fly
Mirum Pharmaceuticals appoints Doug Sheehy as Chief Legal Officer
4M ago
MIRM

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >